News
NNVC
1.610
+1.26%
0.020
NanoViricides moves closer to putting COVID drug in human trials; FQ1 net loss narrows
Seekingalpha · 11/15 13:42
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022 with the Securities and Exchange Commission (SEC) on Monday, November 14, 2022.
ACCESSWIRE · 11/15 11:45
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
By David Willey, Benzinga
News Direct · 10/27 13:25
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission (SEC) on Thursday, October 13, 2022.
ACCESSWIRE · 10/14 10:40
NanoViricides Expects to Have Sufficient Funds to Complete Human Trials for Lead COVID-19 Drug Candidate
NanoViricides Expects to Have Sufficient Funds to Complete Human Trials for Lead COVID-19 Drug Candidate
MT Newswires · 10/14 07:50
Applied DNA, Moderna top healthcare gainers; Kinnate, Owens & Minor lead losers' pack
Gainers: Applied DNA Sciences (APDN) +21%. Moderna (<a href="...
Seekingalpha · 10/12 14:05
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
By Rachael Green, Benzinga
News Direct · 09/19 13:26
Watching NanoViricides Shares As Traders Circulate Article 'Nanotechnology-based strategies against SARS-CoV-2 variants'
https://www.nature.com/articles/s41565-022-01174-5
Benzinga · 08/18 17:56
Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution
Benzinga - Rachel Green
News Direct · 08/10 12:00
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy -
NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox vir...
Benzinga · 08/09 10:47
Short Volatility Alert: NanoViricides, Inc.
On Thursday, shares of NanoViricides, Inc. (NYSE: NNVC) experienced volatile short activity. After the activity, the stock price went up +48.37% to $3.65. The overall sentiment for NNVC has been Neutral.
Benzinga · 08/05 16:23
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close
MT Newswires · 08/04 15:52
InVivo, ChemoCentryx top healthcare gainers; Helius, Enveric lead losers' pack
Gainers: InVivo Therapeutics (NVIV) +114%. Che...
Seekingalpha · 08/04 14:04
Sector Update: Health Care Stocks Sputtering Despite Surging Biotechs
Sector Update: Health Care Stocks Sputtering Despite Surging Biotechs
MT Newswires · 08/04 13:56
NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment
Shares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized therapies for monkeypox, though the Food and Drug Administration said...
marketwatch.com · 08/04 13:01
NanoViricides stock skyrockets 50% on start of drug development program for monkeypox
NanoViricides (NYSE:NNVC) <a href="https://seekingalpha.com/p...
Seekingalpha · 08/04 11:40
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.
ACCESSWIRE · 08/04 10:45
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 05/24 09:29
HIVE, XIN and NEON among mid-day movers
Gainers: Lixiang Education Holding (LXEH) +62%. GeoVax Labs (GOVX) +50%. Sonder Holdings (SOND) +30%. O2Micro International (OIIM) +30%. Evolving Systems (OTC:EVOL) +28%. GoldMining (GLDG) +27%. Neonode (NEON) +24%. Mesa Royalty
Seekingalpha · 05/23 17:06
30 Stocks Moving In Monday's Mid-Day Session
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.
Benzinga · 05/23 16:11
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash. The Company also offers several additional pre-clinical drug development programs, including Herpes Simplex Viruses (HSV-1 that causes cold sores, and HSV-2 that causes genital ulcers), HIV/AIDS, Influenza, Dengue viruses, and Ebola/Marburg.